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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant 
progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not 
arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precur-
sor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal 
Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. How-
ever, the cellular origin of these lesions is still a matter of debate. 
Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this re-
view is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancre-
atic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and 
prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well 
described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are 
various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and 
DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. 
DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA 
methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic 
events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Be-
sides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that 
occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis 
for the development of new effective therapies. 
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1. INTRODUCTION  
  Pancreatic ductal adenocarcinoma (PDAC) is the fourth 
cause of death by cancer in Western countries, while repre-
senting only 3% of the new cancer cases each year [1]. To-
bacco, diabetes, obesity and chronic pancreatitis are de-
scribed as risk factors for PDAC [2]. However, with the ex-
ception of familial PDAC, no high risk population is defined. 
Consequently, screening for PDAC with current imaging 
techniques seems possible only for patients presenting a fa-
milial history of PDAC or already managed for others pan-
creatic diseases. Hence, PDAC is diagnosed at late stage due 
to the absence of specific symptoms (abdominal discomfort 
and abdominal mass due to compression of pancreatic duct) 
[2, 3]. Up to 60% of patients have advanced PDAC at the 
time of diagnosis and are not eligible for surgery; their me-
dian survival is only 3 to 6 months [1]. Resection relies on 
the general condition of the patient, the location, size and 
tumor local invasion. Because of its poor prognosis, im-
provement of PDAC prognostic requires detecting and 
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managing this cancer before regional invasion and metastasis 
[3]. For a better clinical care and a better understanding of 
PDAC, remarkable works have been done to elucidate the 
early events driving pancreatic carcinogenesis. We will first 
describe the main preneoplastic lesions leading to PDAC, to 
further introduce the molecular alterations associated with 
PDAC and their lesion-stage dependent appearance. We will 
finally discuss the molecular marker potential and the clini-
cal interest of such alterations. 
2. PRENEOPLASTIC LESIONS OF THE PANCREAS 
  To date, three types of neoplasic lesion precursor to 
PDAC are described and characterized. The study of these 
lesions is of prime importance to:  
1.  detect and manage PDAC before it becomes invasive 
and incurable. 
2.  better understand PDAC carcinogenesis to elaborate 
new therapies. 
  Development of such lesions is most of the time asymp-
tomatic, and their discovery occurs together with unresecable 
carcinoma. They all follow a multistep progression to inva-
sive cancer classified upon morphological and cytological 
features [2]. The sequential evolution from precursor lesion 16    Current Genomics, 2011, Vol. 12, No. 1  Delpu et al. 
to cancer is still a matter of debate because of the absence of 
early detection and follow-up of these lesions. Main obsta-
cles for precursor detection and follow-up using current di-
agnostic technologies are their small size and the absence of 
high risk population to screen. Consequently, studies are 
usually conducted on fixed resected tissue. In other words, 
the following observations are in favor of a multistep car-
cinogenesis:  
1.  duct lesions are far more common in pancreas with 
infiltrating carcinoma [4, 5]. 
2.  there is an increase in the grade of lesions surround-
ing infiltrating carcinoma [5]. 
3.  patients diagnosed with intraductal mucinous neo-
plasms that are not resected eventually develop 
infiltrating carcinoma [4, 5]. 
2.1. Pancreatic Intraepithelial Neoplasia (PanIN)  
  PanINs are microscopic ductal lesions usually measuring 
less than 1 cm, generally located in the head of the pancreas. 
The small size of PanINs renders illusive their detection by 
MRI (Magnetic Resonance Imagery) or CT (Computed To-
mography). Observation of these lesions is usually fortuitous 
and concomitant to tumor resection. PanINs  are classified 
into 3 grades: PanIN-1 (which are subdivided into PanIN-1A 
and PanIN-1B), PanIN-2 and PanIN-3/ in situ carcinoma 
(Fig. 1). This classification depends on the degree of archi-
tectural and cytological atypia. Briefly, flat and normal epi-
thelia of secondary duct branches show increasing papillary 
architecture and finally adopt a severe cellular atypia and 
frequent mitosis, preceding invasive carcinoma [2]. PanINs 
are the most frequent preneoplastic lesions of the pancreas 
and are observed in 82% of pancreas with pancreatic cancer 
[5]. Low grade PanINs appear to be common lesions found 
in 16-80% of normal pancreas in the absence of neoplasia, 
while high grade PanINs are nearly exclusively associated 
with adenocarcinoma [5-8]. Besides, it is suggested that only 
1% of PanINs evolve into PDAC [9]. As a result, it is tempt-
ing to consider low grade PanINs as benign lesions in ab-
sence of key point mutations. Key genetic events would en-
hance PanIN-1 to PanIN-2 transition, leading to a “no turn-
ing back” development into PDAC. A mouse model express-
ing the constitutively activated K-RAS G12D proto-
oncogene recapitulates PanIN lesions and is the common in 
vivo model for PanINs study [10].  
 
 
 
 
 
 
 
 
 
 
Fig. (1). Microscopic view of Pancreatic intraepithelial neoplasia. 
2.2. Intraductal Papillary Mucinous Neoplasms (IPMN) 
  IPMNs are far less common than PanIN lesions and ac-
count for 3-5% of pancreatic tumors [11]. IPMNs are divided 
into adenoma, borderline and intraductal papillary mucinous 
carcinoma (IPMC) according to the highest degree of dys-
plasia detected (Fig. 2A and 2B) [12]. They comprise large 
lesions with long finger-like papillary architecture, larger 
than 1 cm and delimited by a columnar mucin-secreting epi-
thelium [13, 14]. IPMNs communicate with pancreatic main 
duct. Invasive carcinoma occurs in 20-50% of IPMNs and 
are located on the main pancreatic duct or in the secondary 
branches of the main duct [11]. Additionally, further ana-
tomical criteria depending on the extension of the disease in 
the organ are taken into consideration. In fact, IPMNs are 
classified into three groups: main pancreatic duct IPMN 
(MPD-IPMN), branch duct IPMN (BD-IPMN), and mixed 
IPMN [15]. Current knowledge on IPMN indicates that ap-
proximately 70% of MPD-IPMNs may progress into inva-
sive cancer [15]. Resection represents the only curative 
treatment for IPMNs [15]. The long-term follow-up of re-
sected patients shows 5-year survival rates of 88% for be-
nign and non-invasive lesions and between 36 and 60% for 
IPMC [15, 16].  
 PanINs  and IPMNs  lesions exhibit similar histological 
and molecular features and the distinction between those two 
types of lesions is based on their size and location. Depend-
ing on the lesion origin (main duct or peripheral ductules), 
PanINs and IPMNs can be considered as similar lesions with 
different clinical outcome. Moreover, a mouse model devel-
ops PanIN lesions in addition to cystic lesions of the pan-
creas resembling human IPMNs following TGF- overex-
pression in mutant K-RAS(G12D) transgenic mice [17]. This 
observation is in favor of a common origin of both types of 
lesions. 
2.3. Mucinous Cystic Neoplasms (MCN) 
 MCNs are rare and large (1 to 3 cm) mucin secreting 
neoplasms [13]. This type of lesions is lined by a columnar, 
mucin-filled epithelium and shows a characteristic ovarian-
type stroma beneath the epithelial layer, separating the lesion 
from the pancreatic main duct (Fig. 3A and 3B). MCNs pre-
sent a higher incidence in women as compared to men (ratio 
20 to 1) for unknown reasons. MCNs are classified accord-
ing to their degree of epithelial dysplasia: Mucinous cysta-
denoma, borderline mucinous cystic neoplasms and muci-
nous cystic neoplasms with in situ carcinoma [18]. Because 
of their size and their location, they are often associated with 
non-specific symptoms (abdominal discomfort and abdomi-
nal mass due to compression of pancreatic duct). About 20% 
of MCNs are associated with PDAC [11]. All MCNs may 
progress to mucinous cystadenocarcinoma, which has a very 
low resectability and a very poor prognosis [35, 36, 15]. The 
5 year-survival rate for patient with a surgically resected 
MCNs in the absence of PDAC is close to 100%; such sur-
vival rate falls to 60% when an adjacent neoplasia is diag-
nosed [19]. Izeradjene and co-workers demonstrated that 
mice expressing activated K-RAS(G12D) and deleted for 
Smad4/Dpc4 develop pancreatic cystic neoplasms in the   
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body and the tail of the pancreas in addition to low-grade 
PanINs [20]. According to the size of these lesions, IPMNs 
and MCNs can be detected using CT and MRI and present a 
better prognostic as compared to microscopic lesions PanIN. 
3. CELLULAR ORIGIN OF PRENEOPLASTIC LE-
SIONS 
  All three known precursor lesions bear ductal epithelial 
cells characteristics, but the precise cellular origin of these 
lesions is still highly debated.  
  In mice, induction of short term pancreatic injuries using 
caerulein leads to transient acinar cells dedifferentiation into 
mesenchymal cells. These proliferating cells differentiate 
into acinar cells to partially repopulate the wounded organ 
[21]. In mice carrying activating K-RAS mutation, this proc-
ess seems altered and mesenchymal cells differentiation is 
impaired, leading to acinar-to-ductal metaplasia, and then to 
PDAC precursor lesions such as PanINs [21]. The contribu-
tion of immature pancreatic precursors to PDAC progression 
raises the possibility of the presence of pancreatic cancer 
stem cells (CSC). Classically, stem cells constitute a rare 
cellular population characterized by its self-renewal, specific 
cell surface markers, and cellular efflux through multidrug 
resistance channels. Furthermore, these cells give rise to an 
heterogeneous lineage [22-25]. Cancer stem cells may derive 
from this particular population, to acquire a slightly trans-
formed phenotype, known as “minimal deviation” [23].  
 
 
 
 
 
 
 
 
 
 
 
 
A   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
Fig. (2). A: Macroscopic view of an Intraductal Papillary Mucinous Neoplasm. B: Microscopic view of an Intraductal Papillary Mucinous 
Neoplasm. 
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  CSCs have been identified in breast cancer, myeloid leu-
kemia, colon and prostate cancer [26]. The identification of 
such CSCs in the pancreas only relies on the presence of cell 
surface markers and the up-regulation of Sonic Hedgehog 
pathway (SHH), participating in self renewal mechanisms 
[27]. Zhou and co-workers reported dye efflux capacities of 
PANC-1 cells side population in vitro but not in vivo [22, 
28]. If the capacity of efflux, the location and the rarity of 
these cells within the tumor would contribute to explain their 
resistance against conventional therapies, this evidence only 
suggests the “stem” nature of a subpopulation of pancreatic 
cancer cells and further studies will be required to conclude 
on their status. Furthermore, the existence of pancreatic can-
cer stem cells implies the existence of adult pancreatic stem 
cells to deviate from. To date, existence of such cell type is 
still a matter of debate [21, 29]. On the other hand, one could 
hypothesize that a so-called stem cell population would 
rather arise from a subpopulation of de-differentiated acinar 
cell, unable to fully differentiate into epithelial ductal cells. 
Additionally, adult stem cell performing minimal deviation 
and leading irremediably to PDAC is contradictory because 
of the frequent observation of low grade PanINs in normal 
pancreas. “Cancer stem cell” would then originate from de-
differentiation failure during pancreas regeneration. The 
status of mesenchymal cell would allow them to migrate, 
colonize new niche and then, enter dormancy. Consequently, 
residual undifferentiated pancreatic cell in resection margin 
would explain frequent relapse of patients after surgery, to-
gether with distant, microscopic metastasis. 
4. DNA ALTERATIONS IN PRENEOPLASTIC LE-
SIONS  
  Classically, sequential evolution from precursor lesion to 
PDAC involves the accumulation of diverse molecular 
changes. Such alterations provide precious evidence for un-
derstanding PDAC development, and devising new detection 
and diagnostic tools. However, little is known about the ki-
netic of appearance of these molecular events. To date im-
provement in high throughput sequencing technologies pro-
vides whole genomic methylation patterns and single point 
mutation analysis. Moreover, recent design of mouse models 
recapitulating preneoplastic lesions of the pancreas allowed 
great advances in our understanding of PDAC related mo-
lecular alterations.  
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Fig. (3). A: Macroscopic view of Mucinous Cystic Neoplasm. B: Microscopic view of Mucinous Cystic Neoplasm. 
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4.1. Genetic Alterations 
4.1.1. Large Chromosomal Alterations in PDAC 
  Genetic alterations in pancreatic cancer have been de-
scribed for decades. In the late 80’s, Korc and coworkers 
reported that Epidermal Growth Factor Receptor (EGFR) 
altered expression is linked with qualitative and quantitative 
chromosomal defects such as reciprocal translocation and 
chromosomal deletion of chromosome 7 [30]. EGFR belongs 
to the cell surface receptor family with tyrosine kinase activ-
ity. EGFR activation by its ligand EGF leads to signal trans-
duction through three main pathways: Mitogen-activated 
protein (MAP) kinase cascade, phosphotidylinositol-3 kinase 
(PI3K) pathway and the signal transducer and activator of 
transcription (STAT) pathway, promoting cell division and 
survival [31]. In PDAC as in other cancers, EGFR is fre-
quently subjected to gene amplification (65% of cases) [32-
34]. Intragenic mutations are far less common (3.6% of 
PDAC) and lead to EGFR over-activation [35]. Overexpres-
sion of EGFR is an early event in pancreatic carcinogenesis 
and occurs from PanIN-1 stage to invasive PDAC [36]. Be-
sides, 61.2% of malignant MCNs exhibit increased expres-
sion of EGFR, whereas EGFR is not detected in any of be-
nign MCN [37].  
  Recent studies based on high throughput sequencing ap-
proaches described numerous original regions prone to fre-
quent large genetic alterations during carcinogenesis. One 
hundred and forty four minimal regions identified in 119 
independent loci are subjected to such changes and play a 
potential role in tumor progression, with loci encoding for 
p16INK4A, TP53, MYC, K-RAS2, and AKT2 previously 
described as duplicated or deleted in PDAC [38]. Using Rep-
resentational Oligonucleotide Microarray (ROMA), Lucito et 
al. identified 31 amplifications  and 25 deletions involving 
more than 500 genes in familial pancreatic cancer [39]. 
Campbell et al. recently analyzed patterns of genomic insta-
bility in PDAC and pancreatic metastasis [40]. Resulting 
evidence indicates that PDAC bears specific pattern of ge-
nomic alterations (deletion, fold-back inversion, tandem du-
plication), as compared to other type of cancer. Moreover, 
these alterations are sequentially detectable from primary 
tumor to metastasic disease. However, the status of such 
alterations in preneoplastic lesions is unknown. Additionally 
to tumor suppressor genes, genetic instability occurs in spe-
cific regions encoding microRNAs [41]. MicroRNAs 
(miRNA) are small non coding RNAs (20-22nt) involved in 
the negative regulation of mRNAs translation [42]. miRNAs 
may regulate about 60% of cellular processes and their de-
regulation is a critical event in carcinogenesis. Alteration in 
miRNAs expression is a hallmark of cancer and leads to on-
cogene loss of repression or direct tumor suppressor gene 
downregulation [42]. Such deregulation leads to a wide 
range of consequences, influencing tumor progression in-
cluding cell cycle regulation, epithelial to mesenchymal tran-
sition, cellular migration and angiogenesis. Over 130   
microRNAs are documented as deregulated in PDAC and 
pancreatic cancer cell lines but few data exist on the precise 
mechanisms of such alteration [43, 44]. Similarly to tumor 
suppressor genes, miRNAs expression alteration can occur 
anywhere from early to late precursor lesions during PDAC 
progression. In fact 52.5% of miR genes are in cancer-
associated genomic regions or in fragile sites, subjected to 
loss of heterozygosity, minimal regions of amplification, or 
common breakpoint regions [45].  
4.1.2. Single Point Mutation  
  Single point mutations correspond to single base substitu-
tion in DNA sequence. Such replacement can have various 
outcomes depending on the genomic region targeted and the 
new codon generated by this modification. Many tumor sup-
pressor genes and proto-oncogenes are associated with acti-
vating or inhibiting mutation in PDAC. If many of these mu-
tations are known for decades, the dynamic of their ap-
pearence in preneoplastic lesions of the pancreas have long 
remained unclear. Here, we present a non-exhaustive list of 
genes for which single point mutation have been identified in 
preneoplastic grades. The K-RAS gene (Kirsten-RAS) en-
codes a RAS homolog that belongs to the cytosolic GTPase 
family. A single amino acid substitution from G to D at 
codon 12 is responsible for a constitutive activation observed 
in up to 95% (60-95%) of PDAC and therefore represents the 
most common mutation for this cancer [46]. Oncogenic K-
RAS activates the MAP Kinase, and/or the PI3K pathways, 
leading to increased mitogenic activity. K-RAS mutation is 
an early event during pancreatic carcinogenesis and occurs in 
35% of PanIN-1 lesions and reaches 75% in PanIN-3 [6, 46]. 
The low frequency of K-RAS mutation in PanIN-1 suggests 
that K-RAS mutation facilitates the progression from low-
grade to high-grade PanINs but is not a sine qua non condi-
tion to PanIN-1 initiation. On the other hand, K-RAS G12D 
mutation specifically expressed in the whole mice pancreas 
at the embryonic stage is sufficient to develop PanIN lesions 
[10, 47]. K-RAS mutation is observed in a third of IPMN 
adenomas and its mutation frequency increases with lesion 
grade (50 % of mutated K-RAS in IPMN borderline and 
IPMC with invasion) [12, 48]. Similarly, MCNs harbor K-
RAS mutation in 20% of benign MCNs, 33% of borderline 
lesions, and 89% of malignant MCNs [49]. B-RAF is a 
member of the RAF family, belonging to the MAP Kinase 
pathway. B-RAF mutation is observed in 7%-15% of PDAC 
[12, 50]. Activating intragenic mutation of B-RAF leads to 
activation of RAF effector MEK. Previous reports proposed 
that K-RAS and BRAF mutation are exclusive in PDAC [2, 
51] and that oncogenic B-RAF would represent an alterna-
tive for MAP Kinase pathway activation in the absence of K-
RAS mutation [50]. Ishimura and co-workers reported con-
comitant K-RAS and BRAF activating mutations in tumor 
samples [50], with no clinicopathological incidence as com-
pared to K-RAS mutation alone, suggesting that there is no 
cumulative effect and that the addition of the two mutations 
is not an advantage for tumor progression. When compared 
to the very high K-RAS mutation frequency in preneoplastic 
lesions, mutation of B-Raf only occurs in 2.7% of IPMTs 
[12]. The study of B-RAF mutation in PanINs and MCNs is 
still to be done. As mentioned above, Schonleben et al re-
ported that EGFR mutations are very infrequent in IPMNs 
(no mutation found in 36 IPMT) whereas another group re-
ported EGFR point mutation in 7.5% of Intestine Type 
IPMNs [48, 52]. To date, no mutational analysis of EGFR 
concerning PanIN and MCN lesions are available. DKN2A is 
a tumor suppressor gene which encodes the P16 tumor sup-
pressor protein. P16 indirectly provokes Rb protein phos-
phorylation and its loss of function leads to entry in cell cy-20    Current Genomics, 2011, Vol. 12, No. 1  Delpu et al. 
cle and acute cell proliferation. P16 is the most frequently 
inactivated tumor suppressor gene in PDAC and is observed 
in up to 95% of patients [13]. Interestingly, different mecha-
nisms are responsible of its inactivation including homozy-
gous deletion, intragenic mutation and epigenetic silencing 
by promoter methylation (40%, 40% and 15% of PDAC re-
spectively) (see paragraph below) [2]. All of these invalidat-
ing modifications arise at late stages of pancreatic carcino-
genesis, in both PanINs and IPMNs (adenoma 45%, border-
line 50%, IPMC 53%) with a greater incidence in PanINs 
(PanIN-1 30-44%, PanIN-2 80%, PanIN-3 92-100%) [53]. 
However, these data are based on protein expression studies 
using immunohistochemistry detection and does not identify 
the alterations leading to p16 loss of function. Cell line de-
rived from non invasive MCNs  harbors p16 mutation at 
codon 58, indicating that such genetic alteration is an early 
event in MCNs multistep development [54]. SMAD4/DPC4 
(Mothers against decapentaplegic homolog 4/Deleted in 
Pancreatic Cancer 4) is subjected to frequent deletion or in-
tragenic mutation in PDAC (55%) [55]. SMAD4 is a key 
actor in TGF beta signaling pathway, and activates transcrip-
tion of cell cycle inhibitory factors, particularly p21 [56]. 
Thus, loss of SMAD4 leads to relapse of growth inhibition 
and uncontrolled proliferation [53]. SMAD4 expression is 
normal in low grade PanINs (PanIN-1 and -2) and inactiva-
tion occurs at late stage in 31% of PanIN-3 [55]. Similarly, 
SMAD4 expression is normal in adenoma and borderline 
IPMNs and occurs in 38% of IPMCs [53]. During MCNs 
development, DPC4 loss of expression is a late event, as the 
protein is not detectable at invasive stage [57].  
  Mutation in Tumor Protein 53 (TP53) locus is the most 
common single point mutation in human cancer. TP53 acts 
as a transcription factor and binds to DNA to activate tran-
scription of genes regulating DNA repair, cell cycle and 
apoptosis [56]. Inactivating mutations in TP53 are observed 
in up to 75% of pancreatic cancers [13]. Nonetheless, muta-
tional inactivation of TP53 is a late event during PanIN 
multistep progression to PDAC (0% in PanIN-1 to 12% in 
PanIN-3) and seems to be more frequent in IPMN (30% in 
IPMN adenoma, 30% in IPMN borderline and in IPMC 50-
63%) [2, 13, 53, 56, 58]. Cell line derived from non invasive 
MCN harbors p53 mutation at codon 132, indicating that 
such genetic alteration takes place before invasive MCN 
grade [54]. Whole genome analysis approach represent the 
next step for the discovery of new actors that have not previ-
ously been linked to cancer progression or initiation. The 
genome-wide study of twelve prospective cohorts of PDAC 
patients identified SNPs located in three novel genomic re-
gions associated with the risk of PDAC [59]. Two of these 
regions are coding region while the third locus on chromo-
some 13q22.1 maps to a large non coding region that re-
quires further characterization. 
4.2. Epigenetic Alterations 
 DNA  methylation consists of the addition of a methyl 
(CH3) residue on cytosine preceding a guanosine, known as 
CpG dinucleotides (p stands for phosphate). This modifica-
tion is catalyzed by a  DNA methyltransferase family 
(DNMT1, 3a and 3b). CpG dinucleotides are not equally 
interspaced in the genome and are frequently grouped in 
CpG island. Sixty percent of gene in human genome display 
one or more CpG islands in their promoter and therefore can 
be potentially inactivated by methylation. Only 5% of these 
promoters are methylated. They promote transcription of 
genes involved in development , or subject to X chromosome 
inactivation and genomic imprinting [60]. Alteration in DNA 
methylation pattern is a hallmark of cancer and is associated 
with an overexpression of DNMTs [61, 62]. Interestingly, 
whole genome analysis indicates global hypomethylation 
and only local hypermethylation [63, 64]. Global hypometh-
ylation phenomenon despite DNMTs overexpression may 
involve targeted DNA methylation [65]. However, the mo-
lecular mechanisms involved in such regulation remain un-
clear to date. Frequent over expression of proto-oncogene in 
cancer may be linked to their genomic sequence hypomethy-
lation. Understanding global methylation patterns has long 
been limited by technological concerns limiting the number 
of genes analyzed. Using cell lines and tumor samples, Sato 
and co-workers analyzed the methylation status of a subset 
of 18 genes previously identified as over expressed in PDAC 
as compared to normal pancreas [66]. The authors describe 
that Mesothelin and Claudin 4 genes are frequently hy-
pomethylated in PDAC (92% and 89%, respectively) and 
their methylation status correlates with their expression pat-
tern. On the other hand, hypermethylation occurs during 
cancer, and may lead to gene silencing. Hypermethylation is 
responsible for the inactivation of numerous tumor suppres-
sor genes and can occur independently or additionally to 
intragenic mutation [66-68]. As an example, P16 is equally 
subjected to mutation or hypermethylation, whereas 
RASSF1A, Cyclin D2, SOCS-1, APC are tumor suppressor 
genes silenced only following hypermethylation of their 
promoting sequence in PDAC [69-71]. By comparing the 
whole methylome of PDAC with healthy tissue using high 
throughput technologies, Omura et al. determined that 
MDF1, miR-9-1, ZNF415, CNTNAP2 and EVOLV-4 were 
the most frequently methylated loci among 88000 probes 
tested [68]. Interestingly, only miR-9-1 and CNTNAP2 have 
previously been linked to cancer progression or initiation. In 
PanINs, eight genes (CDH3, reprimo, CLDN5, LHX1, 
NPTX2, SARP2, SPARC and ST14) were reported to be dif-
ferentially methylated between normal epithelia and PanIN 
lesions [72]. Interestingly the pattern of methylation during 
the progression of PanINs is variable among genes. This 
work proves that CpG island hypermethylation is an early 
event in PDAC initiation, and its prevalence progressively 
increases during neoplastic progression. Similar results were 
found in IPMNs concerning another subset of genes includ-
ing P16, ppENK, P14, P15, P17, APC, hMLH, E-Cadherin 
and MGMT [73]. Gene methylation status have not been 
studied yet in MCN. Taken together, DNA aberrant hyper-
methylation correlates with DNMT1 over expression in Pan-
INs, and strongly suggests that early methylation may induce 
precursor lesion progression, and is probably not a conse-
quence of deregulated cellular processes [62]. As stated be-
fore, miRNAs have been linked to cancer initiation or pro-
gression but miR-148a, 107, 34a and Mir 9-3 are the only 
miRNA genes hypermethylated in cancer [41, 74-76]. Few 
miRNAs are described as early actors of pancreatic carcino-
genesis. MiR-148a is described to be down regulated in nu-
merous cancers (colon, melanoma, lung cancer) [41]. Our 
recent works demonstrated mir-148a down regulation by 
DNA hypermethylation in PanIN-1 and -2 [74]. To date, no Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis  Current Genomics, 2011, Vol. 12, No. 1    21 
data are available concerning miR-148a expression in 
IPMNs or MCNs. On the other hand, miR-200 and miR-34a 
alteration of expression are late events in PDAC. Indeed, 
miR-200 overexpression takes place in invasive PDAC con-
sequently to its genomic sequence hypomethylation and indi-
rectly suppresses E-cadherin expression and contributes to 
epithelial to mesenchymal transition [77]. Inversely, miR-
34a is down-regulated by hypermethylation of its DNA cod-
ing sequence and its re-expression induces senescence and 
cell cycle arrest [76, 78]. Consistent work has been done on 
molecular characteristics of invasive cancer. Further efforts 
will be needed to improve our understanding of molecular 
alterations in preneoplactic lesion during their multistep evo-
lution. In fact, most of the studies are performed on PanIN 
lesions, due to their higher frequency as compared to IPMNs 
and MCNs. Further work is needed to better understand 
IPMN and MCN carcinogenesis. As described above, altera-
tion in miRNAs expression caused by aberrant DNA methy-
lation is an early event in PDAC carcinogenesis, but the con-
sequences of such modification is not clearly defined. Be-
cause miRNAs are fine regulator of multiple cellular path-
ways and because their alteration occurs very early in the 
oncogenic cascade, it is tempting to speculate that miRNAs 
may induce carcinogenesis. Transgenic mouse models for 
miR-1792, miR-21, miR-29 or miR-155 miRNAs were 
recently published [79-82]. In these models, expression of 
miR specifically targeted to the hematopoietic compartment 
induced lymphopathies. To date, no PDAC transgenic mouse 
model with impaired miRNAs expression is available.  
5. GENERAL INTEREST OF GENETIC MUTATION 
AND METHYLATED GENE AS BIOMARKERS FOR 
PDAC 
  For routine clinical use, molecular markers must be 
highly sensitive, highly specific and easy to access. To date, 
current molecular markers mainly rely on variations of pro-
teins/mRNAs expression or histological features. However, 
the use of such markers presents several issues: i: proteins 
and mRNAs are not stable and are subject to extensive deg-
radation following collection and ii: histological and protein 
analysis require consequent amount of tissue. PDAC grading 
is currently based on CA 19-9, mucin expression or his-
tological study from pancreatic fluids or biopsy. Determina-
tion of new molecular markers to improve early diagnosis of 
this malignancy is impeded by the low frequency of PDAC 
(4% of new cases of cancer) and its late diagnosis [1]. Ge-
netic and epigenetic alterations both represent an important 
source of biomarkers for PDAC early detection. In compari-
son to standard molecular markers, DNA mutation and DNA 
methylation patterns confer the advantage to be stable and 
quantified from very low amounts of material from diverse 
biological samples (biopsies, urines, stool, blood…). 
5.1. Diagnostic Marker 
  Recent studies considered K-RAS mutation analysis in 
Fine Needle Aspiration (FNA) for PDAC diagnosis, and 
achieved respectable sensitivity and specificity [83-85]. Our 
work indicates that miR-148a genomic sequence hypermeth-
ylation also discriminate PDAC from chronic pancreatitis 
[74]. Moreover, 289 methylation patterns in 2016 genes have 
been demonstrated to successfully discriminate healthy tis-
sue from PDAC [67]. However, this pattern is not specific 
for PDAC among other types of cancer and requires biopsy 
so is not suitable for large scale screening of PDAC. Finally, 
recent works proved that measuring methylation patterns 
specific for PDAC in blood samples is possible with a sensi-
tivity of 81.7%, and can be a first step towards a sensitive, 
specific and non-invasive diagnosis tool [86].  
5.1.1. Predictive Marker 
  Another promising application of genetic mutation and 
methylated gene derived biomarkers  is to predict patients 
resistance to therapy. According to Tan and co-workers, 
methylation status of GSTM1 and ONECUT2_E96_F is pre-
dictive of tumor chemosensitivity [67]. Determination by 
high throughput technologies of global methylation patterns 
in patients diagnosed for PDAC and correlation with re-
sponse to gemcitabine treatment after follow up could iden-
tify predictive and surrogate markers for chemotherapeutic 
response [67]. 
6. SUMMARY AND FUTURE DIRECTIONS 
  Despite recent progress in understanding the multistep 
progression from precursor lesion to invasive cancer and 
metastasis, PDAC is still detected too late for surgical treat-
ment. As a consequence, early diagnosis of this disease is 
urgently needed. Detecting alterations in DNA methylation 
patterns is one most promising avenue for biomarker discov-
ery for PDAC. It is our belief that the future use of unbiased 
high throughput sequencing will allow the characterization 
of whole methylation patterns to identify new biomarkers 
helpful for PDAC diagnosis and prognosis. 
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